Effective bridging therapy before CAR T-cell infusion requires balancing disease control and tolerability.
In Hematology Highlights by Decera Clinical Insights, Dr Joshua Richter explores dosing, scheduling, and adverse effect management with selinexor-based therapy.
Watch: https://bit.ly/4wGOqgx
Effective bridging therapy before CAR T-cell infusion requires balancing disease control and tolerability. In Hematology Highlights by Decera Clinical Insights, Dr Joshua Richter explores dosing, scheduling, and adverse effect management with selinexor-based therapy. Watch: https://bit.ly/4wGOqgx
0 vue
Publié le 29/10/2026 15:01
0:34
Effective bridging therapy before CAR T-cell infusion requires balancing disease control and tolerability.
In Hematology Highlights by Decera Clinical Insights, Dr Joshua Richter explores dosing, scheduling, and adverse effect management with selinexor-based therapy.
Watch: https://bit.ly/4wGOqgx
0 commentaire
?